The Role of Sarcopenic Obesity in Hyperlipidemia and Its Impact on Metabolic Health

Sarcopenic obesity, a condition characterized by the simultaneous presence of reduced muscle mass and increased adiposity, has emerged as a critical health concern in the context of metabolic disorders. This review examines the complex interplay between sarcopenic obesity and hyperlipidemia, focusing on the implications for metabolic health. The coexistence of diminished muscle mass and excess fat alters lipid metabolism, leading to elevated circulating lipid levels and exacerbating cardiovascular risks. Mechanisms contributing to this dysregulation include insulin resistance, chronic low-grade inflammation, and altered adipokine secretion, all of which are exacerbated in sarcopenic obesity. Moreover, the condition predisposes individuals to metabolic syndrome, type 2 diabetes, and cardiovascular diseases, highlighting the need for targeted therapeutic strategies. This article discusses the underlying pathophysiology, the role of lifestyle factors, and potential interventions aimed at mitigating the impact of sarcopenic obesity on hyperlipidemia and overall metabolic health. Keywords: Sarcopenic obesity, hyperlipidemia, metabolic health, insulin resistance, inflammation, adipokines, cardiovascular disease, metabolic syndrome